Kendle sets up in Ahmedabad

By Gareth Macdonald

- Last updated on GMT

Related tags: Southeast asia, India

US CRO Kendle has opened a new services centre in India, attracted by the country’s thriving contract research sector and favourable climate for clinical trials.

The 14,000 sqft centre, in the Ahmedabad-Gandhinagar special economic zone (SEZ), will provide clinical data management, pharmacovigilance and biostatistics services to sponsors running trials in the region.

Kendle has had a presence in India​ since 2004 with its unit in New Delhi and has been expanding to allow its clients increased access to the nation’s favourable research conditions.

COO Stephen Cutler said that: "Growth in India is a key component of our strategy and will be very important to the future​" adding that an "expanded presence in Asia, and in India in particular, creates efficiencies in the clinical development process​.”

In an interview in the Business Standard Cutler contrasted India with Asia’s other contract research hotbed China, explaining that “India's edge… lies in its favourable regulatory environment and research initiatives as well as investor-friendly duty structure.”

The new unit will begin operations with a staff of fifty although Kendle plans to scale up this up in the next few years, benefiting from the units “proximity to multiple universities” in and around Ahmedabad.

This expansion, according to company senior director of South East Asia operations Bharat Doshi, is likely to require “would require around 84,000 square feet of space to house around 300 associates.”

SEZ benefits

Aside from access to large population centres and proximity to a number of pharmaceutical manufacturers the Ahmedabad-Gandhinagar also provides Kendle with others benefits due to its status as an SEZ.

Operating in an SEZ gives contract research organisations (CROs) like Kendle, and GVK Biosciences who set up there in March​, staged tax benefits, including a five year 100 per cent exemption on export income.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars